HemaSphere (Jun 2022)

S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7)

  • A. Sureda,
  • J. Westin,
  • F. L. Locke,
  • M. Dickinson,
  • A. Ghobadi,
  • M. Elsawy,
  • T. van Meerten,
  • D. B. Miklos,
  • M. Ulrickson,
  • M.-A. Perales,
  • U. Farooq,
  • L. Wannesson,
  • L. Leslie,
  • M. J. Kersten,
  • C. A. Jacobson,
  • J. M. Pagel,
  • G. Wulf,
  • P. Johnston,
  • A. P. Rapoport,
  • L. I. Gordon,
  • Y. Yang,
  • A. Peng,
  • L. Du,
  • J. T. Snider,
  • J. Shah,
  • M. Schupp,
  • P. Cheng,
  • C. To,
  • O. O. Oluwole

DOI
https://doi.org/10.1097/01.HS9.0000843736.56298.a7
Journal volume & issue
Vol. 6
pp. 112 – 113

Abstract

Read online

No abstracts available.